BOOK A LONG COVID TEST

attomarker

technology overview

7 reasons

Technology Overview

Attomarker has developed a multiplex assay platform that measures biomarker concentrations in blood samples. Blood contains thousands of proteins that have normal levels in good health but change during illness. Our approach focuses on personalisation – defining what’s normal for each individual in good health. By simultaneously measuring multiple biomarkers, we create profiles that deepen our understanding of health evolution and disease progression. Our technology significantly reduces the burden of blood sampling, requiring only a small volume to measure up to 20 biomarkers and deliver results in as low as 7 minutes. What started as a research project is now a reality and on sale in three countries.

The core technology developed by Attomarker utilises an array of gold nanoparticles printed into sensor spots. These spots facilitate the flow of a blood sample over them, and when illuminated from below, they scatter light. This scattering changes according to the mass of protein on the surface of the nanoparticles (see Figure 1). The mass sensing is unique because it allows a proper measurement to be made that is fully quantitative. This advancement aims to establish a new global standard for biomarker tests, ensuring that all laboratories provide results in standard units, thereby eliminating local variations in standards.

Looking ahead, Attomarker envisions a future where developing advanced test panels will revolutionise healthcare outcomes. By profiling complex biological systems in near real-time, these innovative tests will pave the way for creating precise biological models.

Liscar 6

The Light Scattering Array Reader (LISCAR) version 6 (see Figure 2) is an award-winning CE-marked bench-top instrument that can be used in clinics next to the patient at the point-of-care where the rapidity of this test can make a difference. It operates both as a stand-alone unit in clinics and in a laboratory setting. It is easy to use and uploads the results to the Cloud for enhanced quality control as soon as measurements are completed. Attomarker’s COVID Antibody Isotype Spectrum Test and Flu Antibody Spectrum Test amaresearch test is currently in use in selected clinics worldwide.

A suite of different chips is currently in our rapid development pipeline including a Fatty Liver Test that looks at the state of the liver from healthy through the onset of type 2 diabetes to cirrhosis. In addition, a full profile of the hormones of the menstrual cycle will help us to understand properly fertility and hormone replacement therapy in the menopause.

7 reasons

Handheld

Attomarker’s technology is advancing towards home use with a new handheld device that maintains full quantitative capability, capable of measuring multiple biomarkers from a fingerprick sample blood.

This device, illustrated in Figure 3, utilises an iPhone to capture changes in the brightness of gold nanoparticles, compute the results, and transmit them securely to the Cloud. This innovation enables laboratory-quality measurements verified remotely in the Cloud, and swiftly communicated to a clinician for teleconsultations. Our vision for the handheld device extends to include a rapid infection chip to aid in sepsis management and food allergy screening.

Attomarker is dedicated to developing world-leading diagnostic capabilities, ensuring these advancements reach all corners of the globe.